Can The COVID Approach Be Used For Other Therapeutics? FDA Speed Is Factor, Pfizer’s Bourla Says

Execs debate how to achieve COVID-fast development of all products; challenges include reforming corporate bureaucracies and getting regulators more funding. Regeneron’s Schleifer says trouble distributing its monoclonal antibodies stemmed from government’s ‘maniacal focus on vaccines.’